Clinical Trial Update: Study of PCLX-001 in R/R Advanced Solid Malignancies and B-cell Lymphoma [Phase 1]

View source ↗

Summary

Phase 1 study of PCLX-001 in relapsed/refractory advanced solid tumors and B-cell non-Hodgkin lymphoma has completed, with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-cell Non-hodgkin Lymphoma
• Solid Tumor

Drugs mentioned

• PCLX-001

Snippet

Sponsor: Pacylex Pharmaceuticals | Conditions: B-cell Non Hodgkin Lymphoma, Advanced Solid Tumor | Phase 1 | Status: COMPLETED | Results posted: 2025-04-17